company background image
GMTX logo

Gemini Therapeutics NasdaqGM:GMTX Stock Report

Last Price

US$1.35

Market Cap

US$58.5m

7D

-12.9%

1Y

-53.6%

Updated

30 Dec, 2022

Data

Company Financials +

Gemini Therapeutics, Inc.

NasdaqGM:GMTX Stock Report

Market Cap: US$58.5m

This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

GMTX Stock Overview

Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD).

GMTX fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Gemini Therapeutics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Gemini Therapeutics
Historical stock prices
Current Share PriceUS$1.35
52 Week HighUS$3.10
52 Week LowUS$1.16
Beta-0.12
1 Month Change-21.51%
3 Month Change-17.68%
1 Year Change-53.61%
3 Year Changen/a
5 Year Changen/a
Change since IPO-86.89%

Recent News & Updates

Recent updates

Shareholder Returns

GMTXUS BiotechsUS Market
7D-12.9%-2.9%-0.6%
1Y-53.6%6.6%25.4%

Return vs Industry: GMTX underperformed the US Biotechs industry which returned -10.7% over the past year.

Return vs Market: GMTX underperformed the US Market which returned -23.1% over the past year.

Price Volatility

Is GMTX's price volatile compared to industry and market?
GMTX volatility
GMTX Average Weekly Movement8.4%
Biotechs Industry Average Movement11.0%
Market Average Movement5.9%
10% most volatile stocks in US Market15.9%
10% least volatile stocks in US Market2.9%

Stable Share Price: GMTX's share price has been volatile over the past 3 months.

Volatility Over Time: GMTX's weekly volatility (8%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
201524Georges Gemayelwww.geminitherapeutics.com

Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases.

Gemini Therapeutics, Inc. Fundamentals Summary

How do Gemini Therapeutics's earnings and revenue compare to its market cap?
GMTX fundamental statistics
Market capUS$58.49m
Earnings (TTM)-US$43.42m
Revenue (TTM)n/a

0.0x

P/S Ratio

-1.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
GMTX income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$43.42m
Earnings-US$43.42m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-1.00
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did GMTX perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.